These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39001504)

  • 1. Systemic Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Trial.
    Himmelsbach V; Jeschke M; Lange CM; Scheiner B; Pinter M; Sinner F; Venerito M; Queck A; Trojan J; Waidmann O; Finkelmeier F
    Cancers (Basel); 2024 Jul; 16(13):. PubMed ID: 39001504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
    Bang K; Casadei-Gardini A; Yoo C; Iavarone M; Ryu MH; Park SR; Kim HD; Yoon YI; Jung DH; Park GC; Ahn CS; Moon DB; Hwang S; Kim KH; Song GW; Mazzarelli C; Alimenti E; Chan SL; De Giorgio M; Ryoo BY; Lee SG
    Cancer Med; 2023 Feb; 12(3):2572-2579. PubMed ID: 36812124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.
    Yang Z; Wang S; Tian XY; Xie QF; Zhuang L; Li QY; Chen CZ; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):365-370. PubMed ID: 32553774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival.
    Chagas AL; Felga GEG; Diniz MA; Silva RF; Mattos AA; Silva RCMA; Boin IFSF; Garcia JHP; Lima AS; Coelho JCU; Bittencourt PL; Alves VAF; D'Albuquerque LAC; Carrilho FJ;
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1148-1156. PubMed ID: 31247632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.
    Tran BV; Moris D; Markovic D; Zaribafzadeh H; Henao R; Lai Q; Florman SS; Tabrizian P; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Hoteit M; Levine MH; Cillo U; Vitale A; Verna EC; Halazun KJ; Tevar AD; Humar A; Chapman WC; Vachharajani N; Aucejo F; Lerut J; Ciccarelli O; Nguyen MH; Melcher ML; Viveiros A; Schaefer B; Hoppe-Lotichius M; Mittler J; Nydam TL; Markmann JF; Rossi M; Mobley C; Ghobrial M; Langnas AN; Carney CA; Berumen J; Schnickel GT; Sudan DL; Hong JC; Rana A; Jones CM; Fishbein TM; Busuttil RW; Barbas AS; Agopian VG
    Liver Transpl; 2023 Jul; 29(7):683-697. PubMed ID: 37029083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
    Piñero F; Thompson M; Marín JI; Silva M
    World J Transplant; 2020 Nov; 10(11):297-306. PubMed ID: 33312891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study.
    Chen YY; Chen CL; Lin CC; Wang CC; Liu YW; Li WF; Chen YH
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
    Li BCW; Chiu J; Shing K; Kwok GGW; Tang V; Leung R; Ma KW; She WH; Tsang J; Chan A; Cheung TT; Lo CM; Yau T
    Adv Ther; 2021 Jul; 38(7):3900-3910. PubMed ID: 34061324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
    Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S; Amaddeo G; Manini MA; López MF; Anders M; Pinter M; Rodríguez MJB; Cristóbal MR; Soteras GA; Piñero F; Villadsen GE; Weinmann A; Crespo G; Mazzaferro V; Regnault H; Giorgio M; González-Diéguez ML; Donato MF; Varela M; Wörns MA; Bruix J; Lampertico P; Reig M
    Am J Transplant; 2019 Nov; 19(11):3176-3184. PubMed ID: 31365177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
    De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
    Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
    de'Angelis N; Landi F; Carra MC; Azoulay D
    World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
    JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.
    Li JH; Chen T; Xing H; Li RD; Shen CH; Zhang QB; Tao YF; Wang ZX
    Hepatobiliary Pancreat Dis Int; 2023 Jun; 22(3):245-252. PubMed ID: 35534342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation.
    Andreou A; Bahra M; Schmelzle M; Öllinger R; Sucher R; Sauer IM; Guel-Klein S; Struecker B; Eurich D; Klein F; Pascher A; Pratschke J; Seehofer D
    Clin Transplant; 2016 Jul; 30(7):819-27. PubMed ID: 27107252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
    Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
    J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up Imaging After Liver Transplantation Should Take Into Consideration Primary Hepatocellular Carcinoma Characteristics.
    Dioguardi Burgio M; Ronot M; Fuks D; Dondero F; Cauchy F; Gaujoux S; Dokmak S; Paradis V; Durand F; Belghiti J; Vilgrain V
    Transplantation; 2015 Aug; 99(8):1613-8. PubMed ID: 25710611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study.
    Li Z; Han N; Ren X; Zhang Y; Chu X
    Front Oncol; 2022; 12():833884. PubMed ID: 35433466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
    Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
    Kim HR; Cheon SH; Rha SY; Lee S; Han KH; Chon CY; Lee JD; Sung JS; Chung HC
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):258-69. PubMed ID: 21884437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.